Biochem-Peptides

Write a review

Products

Weightloss

AOD-9604 5mg Vial (Test)

AOD-9604 – Technical Brief (Research-Use-Only) 1. Identity AOD-9604 (“Anti-Obesity Drug 9604”) is a 15-amino-acid fragment of human growth hormone corresponding to residues 176-191 (sequence Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe). It was engineered to isolate hGH’s lipolytic domain while eliminating growth-promoting interaction with the GH receptor, thus avoiding IGF-1 elevation or anabolic effects A B. 2. Mechanistic Highlights 1. Lipolysis activation – Mimics hGH’s fat-mobilising signal, raising cAMP and triggering hormone-sensitive lipase to break down stored triglycerides C A. 2. Inhibition of lipogenesis – Suppresses acetyl-CoA carboxylase activity, reducing formation of new adipocytes C. 3. GH-receptor sparing – Lacks affinity for the full GH receptor, so it does not boost IGF-1 or promote tissue growth, differentiating it from recombinant hGH therapy A. 4. Metabolic neutrality – Early human studies report no meaningful effect on fasting glucose or insulin sensitivity, supporting its “fat-specific” profile C. 3. Safety Profile (clinical context) GI/ Systemic (Common) Mild headache or injection-site irritation in some volunteers (Severe/Rare) None reported to date in short-term studies, Most trials ≤12 weeks Endocrine:- (Common) No IGF-1 rise, no changes in fasting glucose (Severe/Rare) N/A — Distinguishes it from hGH C Overall:- (Common) Well-tolerated at 0.25–1.0 mg kg⁻¹ orally or up to 10 mg day⁻¹ s.c. in Phase I/II trials (Severe/Rare) Mixed efficacy; long-term data lacking - Safety not established for uncontrolled human use 4. Legal Position in the United Kingdom • AOD-9604 is not scheduled under the Misuse of Drugs Act and is uncontrolled. • When supplied strictly “FOR RESEARCH USE ONLY – NOT FOR HUMAN OR VETERINARY USE,” it remains outside the scope of the Human Medicines Regulations 2012. • Any marketing or supply that implies weight-loss or therapeutic benefit reclassifies it as a medicinal product, bringing it under MHRA licensing and enforcement. 5. Practical Laboratory Handling Reconstitution: use sterile 0.9 % Benzyl alcohol Bacteriostatic water, 1–3 mL⁻¹; swirl gently—avoid vigorous shaking. • Storage: aliquot, −80 °C long term; ≤ 30 days at −20 °C once re-suspended. • Typical exploratory dosing (rodent): 250-500mcg subcutaneously, Daily.. --- Bottom line AOD-9604 is a GH-fragment peptide that targets fat metabolism without the growth-stimulating liabilities of full-length hGH. In the UK it may be purchased, possessed, and used exclusively as a laboratory research reagent; any promotion or use outside that remit contravenes medicines legislation.

£40.00

SLU-PP-332 5mg Vial (Test)

SLU-PP-332 – Technical Brief (Research-Use-Only) 1. Identity SLU-PP-332 (4-hydroxy-N-[(Z)-naphthalen-2-ylmethylidene]-benzamide) is a synthetic, yellow crystalline small-molecule discovered at Saint Louis University. It is a potent, non-selective agonist of the estrogen-related receptors (ERRs), displaying its greatest activity at ERR-α with an EC₅₀ ≈ 98 nM A B. Because it is not peptide-based, it shows good metabolic stability and can penetrate cells without a delivery vector. Property Detail Molecular formula C₁₈H₁₄N₂O₂ Molar mass 290.3 g mol⁻¹ Appearance Yellow powder Water solubility < 0.1 mg mL⁻¹; freely soluble in DMSO/DMF A CAS 303760-60-3 --- 2. Mechanistic Highlights 1. ERR-α/β/γ activation – Binding to the ERR ligand-binding domain locks the receptor in its active conformation and strengthens interaction with the co-activator PGC-1α A. 2. Mitochondrial biogenesis – Up-regulation of TFAM and other nuclear-encoded OXPHOS genes increases mitochondrial number and respiratory capacity. 3. Enhanced substrate utilisation – Promotes fatty-acid uptake (↑ CPT-1, MCAD) and β-oxidation, while improving glucose disposal, mimicking many exercise-induced transcriptional changes B. 4. Thermogenesis – Activation of ERR pathways elevates uncoupling protein expression, raising basal energy expenditure in rodent models. --- 3. Safety Profile (pre-clinical) There are no published human data. Rodent studies using 5–20 mg kg⁻¹ day⁻¹ (i.p. or oral gavage) for ≤ 14 days have not reported overt toxicity, but full GLP toxicology is lacking. The compound may cause skin/eye/respiratory irritation; handle in a fume hood and avoid aerosol generation A. These findings do not establish safety for unregulated human exposure. SLU-PP-332 is supplied strictly for laboratory research purposes. --- 4. Legal Position in the United Kingdom • SLU-PP-332 is not scheduled under the Misuse of Drugs Act and is not a controlled substance. • When sold and labelled “FOR RESEARCH USE ONLY – NOT FOR HUMAN OR VETERINARY USE,” it sits outside the Human Medicines Regulations 2012. • Any marketing that implies therapeutic, performance-enhancement, or weight-loss use reclassifies it as a medicinal product, invoking MHRA licensing. --- 5. Practical Laboratory Handling Reconstitution: use sterile 0.9 % Benzyl alcohol Bacteriostatic water, 1–3 mL⁻¹; swirl gently—avoid vigorous shaking. • Storage: aliquot, −80 °C long term; ≤ 30 days at −20 °C once re-suspended. • Typical exploratory dosing (rodent): 250-500mcg subcutaneously, Once or twice Daily. --- Bottom Line SLU-PP-332 is an ERR agonist valued for investigating metabolic rewiring and exercise-mimetic pathways. In the UK it may be purchased, possessed, and employed solely as a laboratory research reagent; any promotion or use beyond this remit contravenes medicines legislation.

£30.00

Sold out

Regeneration and vitality

GHK-CU 100mg Vial

GHK-Cu – Technical Brief (Research-Use-Only) 1. Identity GHK-Cu (Glycyl-L-Histidyl-L-Lysine–Copper) is a naturally occurring tripeptide that chelates a single Cu²⁺ ion. First isolated from human plasma in the early 1970s, it is now synthesized for laboratory study. Endogenous levels fall markedly with age, which partly explains the compound’s prominence in regeneration research A B. Property Detail Sequence Gly-His-Lys · Cu²⁺ Formula (Cu-salt) C₁₄H₂₄N₆O₄Cu Molar mass 403.9 g mol⁻¹ Appearance Blue-green powder Solubility Water > 40 mg mL⁻¹; DMSO miscible CAS 89030-95-5 2. Mechanistic Highlights 1. Collagen & ECM remodelling – Up-regulates COL1A1/2, decorin and glycosaminoglycan synthesis while stimulating matrix metalloproteinases that clear damaged tissue A B. 2. Wound-healing chemoattractant – Recruits immune and endothelial cells to injury sites, accelerating angiogenesis and granulation tissue formation C. 3. Antioxidant & anti-inflammatory actions – Enhances superoxide-dismutase activity, modulates cytokine release, and reduces oxidative DNA damage A C. 4. Hair-follicle & skin renewal – In vitro and small clinical models show increased dermal papilla cell proliferation and improved skin elasticity, supporting its frequent use in cosmetic-grade formulations B. 3. Safety Profile (published data) Domain Common observations Serious / rare signals Notes Topical use Mild, transient erythema or pruritus None reported Most studies ≤12 weeks Parenteral (pre-clin.) No organ toxicity at ≤10 mg kg⁻¹ d s.c. (rodent) Data limited No long-term GLP tox yet Systemic markers No elevation of IGF-1 or fasting glucose — Distinguishes it from hGH fragments Current evidence supports a favourable safety profile in short-term human cosmetic trials, but comprehensive toxicology is lacking; no safety is established for uncontrolled human use. 4. Legal Position in the United Kingdom • GHK-Cu is not scheduled under the Misuse of Drugs Act and is uncontrolled. • Provided it is marketed strictly “FOR RESEARCH USE ONLY – NOT FOR HUMAN OR VETERINARY USE,” supply falls outside the Human Medicines Regulations 2012. • Any wording or imagery implying therapeutic, anti-ageing, or hair-growth benefit reclassifies it as a medicinal product, triggering MHRA licensing. • Supplier duties: Certificate of Analysis ≥ 95 % purity, REACH-compliant SDS, CLP labels with the research-only disclaimer. • Importers should declare CN/HS code 2937 90 000 (“peptide research reagent”) to HMRC. 5. Practical Laboratory Handling • Reconstitution – Dissolve in sterile water or PBS to 2–5 mg mL⁻¹; adjust pH 7.0–7.4. • Storage – Lyophilised powder at −20 °C desiccated; aliquoted solution ≤30 days at −20 °C, avoid repeated freeze-thaw. • In-vitro assays – 0.1–10 µM for fibroblast or keratinocyte studies. • Rodent precedent – 100–300 µg topical daily, or 0.5–2 mg kg⁻¹ s.c. every other day (wound-healing models). • Disposal – Denature with 1 % NaOCl or incinerate as peptide bio-waste per institutional SOP. --- Bottom line GHK-Cu is a small copper-binding peptide with documented pro-repair, antioxidant, and cosmetic effects. In the UK it may be purchased, possessed, and used solely as a laboratory research reagent; any promotion or use beyond that remit violates medicines legislation.

£40.00

Sold out

Weight Management

Obesity management Research

Obesity Management Research

GLP-2 Tirz 40mg Vial (Test)

(GLP-2 Tirz) – Technical Brief (For Research-Use-Only) 1. Identity (GLP2) known in the pharmaceutical industry as Tirzepatide is a 39-amino-acid, lipid-modified peptide that binds and activates both the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R) A. Albumin binding via its C20 di-acid side chain extends the circulation half-life to roughly one week, enabling once-weekly dosing in clinical settings B. 2. Mechanistic Highlights 1. β-cell stimulation (glucose-dependent) – Gs-coupled signalling increases intracellular cAMP and drives insulin granule exocytosis only when plasma glucose is elevated. 2. α-cell suppression – GLP-1R activation dampens glucagon release, curbing hepatic glucose output. 3. Delayed gastric emptying – Enteric–vagal feedback slows nutrient transit, blunting post-prandial glycaemic spikes. 4. Central appetite modulation – Engagement of GIPR/GLP-1R in hypothalamic nuclei reduces hunger, contributing to body-mass reduction seen in trials. 3. Safety Profile (clinical data) GI:- (Common) may cause Nausea, diarrhoea, transient vomiting. (Severe/Rare) gastroparesis Endocrine:- (Common) N/A (Severe/Rare) C-cell tumours in rodents → contraindication in MEN-2 / MTC Pancreas:- (Common) N/A) (Severe/Rare) Low-frequency acute pancreatitis reports CV:- (Common) Mean heart-rate rise ~4–6 bpm (Severe/Rare) Cardiovascular outcome study ongoing Overall, trials highlight robust glycaemic and weight improvements with a safety profile broadly similar to single-agent GLP-1 analogues Important: these findings derive from regulated human studies. No safety data exist for unregulated human use. 4. Legal Position in the United Kingdom • Tirzepatide is not scheduled under the Misuse of Drugs Act and is not a controlled substance. • When supplied “FOR RESEARCH USE ONLY” (in-vitro, ex-vivo, or animal work), it sits outside the Human Medicines Regulations 2012. • Any supply, advertisement, or discussion implying human therapeutic or weight-loss use reclassifies the product as a medicinal product, putting it under MHRA enforcement. 5. Practical Laboratory Handling Reconstitution: use sterile 0.9 % Benzyl alcohol Bacteriostatic water, 1–3 mL⁻¹; swirl gently—avoid vigorous shaking. • Storage: aliquot, −80 °C long term; ≤ 30 days at −20 °C once re-suspended. • Typical exploratory dosing (rodent): 2.5–15mg subcutaneously, once weekly. Bottom line: Tirzepatide is a potent dual-incretin agonist with well-documented metabolic effects in regulated trials. Within the UK it may be purchased, possessed, and used solely as a laboratory research reagent; any use or promotion beyond that scope violates medicines legislation.

£120.00

Sold out

GLP-3 Reta 20mg Vial (Test)

GLP-3 Reta – Technical Brief (For Research-Use-Only) 1. Identity (GLP3) known in the pharmaceutical industry as Retatrutide is a 39-amino-acid peptide engineered to act as a triple agonist at the GLP-1, GIP and glucagon receptors. Lipidation lengthens its half-life so it supports convenient once-weekly dosing in clinical studies A B. 2. Mechanistic Highlights 1. β-cell stimulation (GLP-1 & GIP) – cAMP-driven insulin release only when plasma glucose is elevated. 2. α-cell modulation (GLP-1 & glucagon) – reduced glucagon output curbs hepatic glucose production. 3. Energy expenditure (glucagon arm) – mild increase in basal metabolic rate via hepatic fat oxidation. 4. Gastric emptying delay (GLP-1) – blunts post-prandial glucose excursions. 5. Central appetite suppression (all three receptors in hypothalamus) – drives substantial weight loss; ≥ 22 % mean reduction at 12 mg over 48 weeks in a Phase II trial. 3. Safety Profile (clinical data for context) GI:- (Common) may cause Nausea, vomiting, diarrhoea (dose-dependent). (Serious/Rare) gastroparesis – (uncommon) Metabolic:- (Common) Transient increases in heart rate (3–5 bpm). (Serious/Rare) N/A Endocrine:- (Common) N/A. (Serious/Rare) Rodent thyroid C-cell tumours → class warning Pancreas:- (Common) N/A. (Serious/Rare) Low-frequency acute pancreatitis reports Overall tolerability resembles other incretin mimetics; no excess severe hypoglycaemia outside concomitant insulin/sulphonylurea use. These findings pertain to regulated trials only; they do not establish safety for unregulated human use. 4. Legal Position in the United Kingdom • Retatrutide is not scheduled under the Misuse of Drugs Act and is not a controlled substance. • When supplied “FOR RESEARCH USE ONLY” for in-vitro, ex-vivo or animal experiments, it falls outside the Human Medicines Regulations 2012. • Any marketing or supply implying therapeutic or weight-loss use reclassifies it as a medicinal product and places it under MHRA licensing/enforcement. 5. Practical Laboratory Handling Reconstitution: use sterile 0.9 % Benzyl alcohol Bacteriostatic water, 1–3 mL⁻¹; swirl gently—avoid vigorous shaking. • Storage: aliquot, −80 °C long term; ≤ 30 days at −20 °C once re-suspended. • Typical exploratory dosing (rodent): 2.5–12mg subcutaneously, once weekly.. Bottom line: Retatrutide is a potent triple-incretin agonist showing exceptional weight- and glucose-lowering effects in regulated trials. Within the UK it may be purchased, possessed and used solely as a laboratory research reagent, any promotion or use beyond that scope violates medicines legislation.

£120.00

£1.00

Sold out